Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings

被引：83

作者：

Hummel, Horst-Dieter ^{[1
]}

Kufer, Peter ^{[2
]}

Gruellich, Carsten ^{[3
,4
]}

Seggewiss-Bernhardt, Ruth ^{[1
,5
]}

Deschler-Baier, Barbara ^{[6
]}

Chatterjee, Manik ^{[1
]}

Goebeler, Maria-Elisabeth ^{[7
]}

Miller, Kurt ^{[8
]}

de Santis, Maria ^{[8
,9
]}

Loidl, Wolfgang ^{[10
]}

Dittrich, Christian ^{[11
,12
]}

Buck, Andreas ^{[13
]}

Lapa, Constantin ^{[13
,14
]}

Thurner, Annette ^{[15
]}

Wittemer-Rump, Sabine ^{[16
]}

Koca, Gokben ^{[16
]}

Boix, Oliver ^{[16
]}

Doecke, Wolf-Dietrich ^{[16
]}

Finnern, Ricarda ^{[16
]}

Kusi, Helena ^{[16
]}

Ajavon-Hartmann, Antoinette ^{[16
]}

Stienen, Sabine ^{[2
]}

Sayehli, Cyrus Michael ^{[17
]}

Polat, Buelent ^{[18
]}

Bargou, Ralf C. ^{[6
]}

机构：

[1] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Translat Oncol Early Clin Trial Unit ECTU, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[2] Amgen Res Munich GmbH, Res & Dev, Staffelseestr 2, D-81477 Munich, Germany

[3] Heidelberg Univ, Med Ctr, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

[4] Univ Hosp Dresden, Dept Hematol & Oncol, Haus 27,Fetscherstr 74, D-01307 Dresden, Germany

[5] Sozialstiftung Bamberg, Med Klin 5, Buger Str 80, D-96049 Bamberg, Germany

[6] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Translat Oncol, Josef Schneider Str 6, D-97080 Wurzburg, Germany

[7] Univ Hosp Wurzburg, Med Klin 2, Translat Oncol Early Clin Trial Unit ECTU, Oberdurrbacherstr. 6, D-97080 Wurzburg, Germany

[8] Charite Univ Med Berlin, Dept Urol, Charitepl 1, D-10117 Berlin, Germany

[9] Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

[10] Ordensklinikum Linz GmbH Elisabethinen, Dept Urol, Fadingerstr 1, A-4020 Linz, Austria

[11] Kaiser Franz Josef Spital, Inst Translat Res Vienna ACRI TR VIEnna, Appl Canc Res, Bernardgasse 24-2, A-1070 Vienna, Austria

[12] Kaiser Franz Josef Spital, Ctr Oncol & Hematol, Bernardgasse 24-2, A-1070 Vienna, Austria

[13] Univ Hosp Wurzburg, Dept Nucl Med, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[14] Univ Augsburg, Med Fac, Nucl Med, Stenglinstr 2, D-86156 Augsburg, Germany

[15] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[16] Bayer AG, SBU Oncol, Pharmaceut, D-13353 Berlin, Germany

[17] Univ Hosp Wurzburg, Med Klin 2, Translat Oncol Early Clin Trial Unit ECTU, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[18] Univ Hosp Wurzburg, Dept Radiat Oncol, Josef Schneider Str 11, D-97080 Wurzburg, Germany

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 02期

关键词：

AMG; 212; BAY; 2010112; bispecific T-cell engager (BiTE (R)) immune therapy; pasotuxizumab; PSMA; prostate cancer; MEMBRANE ANTIGEN; T-CELLS; NIVOLUMAB; CHEMOTHERAPY; ANTIBODY; PEMBROLIZUMAB; IPILIMUMAB; REGRESSION; CARCINOMA;

D O I：

10.2217/imt-2020-0256

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE (R)) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. Patients & methods: We assessed once-daily subcutaneous (SC) pasotuxizumab. All SC patients developed antidrug antibodies; therefore, continuous intravenous (cIV) infusion was assessed. Results: A total of 47 patients received pasotuxizumab (SC: n = 31, 0.5-172 mu g/d; cIV: n = 16, 5-80 mu g/d). The SC maximum tolerated dose was 172.0 mu g/d. A sponsor change stopped the cIV cohort early; maximum tolerated dose was not determined. PSA responders occurred (>50% PSA decline: SC, n = 9; cIV, n = 3), including two long-term responders. Conclusion: Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. Clinical trial registration:NCT01723475 (ClinicalTrials.gov)

引用

页码：125 / 141

页数：18

共 50 条

[1] Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Rathkopf, Dana
Liu, Glenn
Carducci, Michael A.
Eisenberger, Mario A.
Anand, Aseem
Morris, Michael J.
Slovin, Susan F.
Sasaki, Yasutsuna
Takahashi, Shunji
Ozono, Seiichiro
Fung, Nga Kit Eliza
Cheng, Shinta
Gan, Jinping
Gottardis, Marco
Obermeier, Mary T.
Reddy, Jyotsna
Zhang, Steven
Vakkalagadda, Blisse J.
Alland, Leila
Wilding, George
Scher, Howard I.
CLINICAL CANCER RESEARCH, 2011, 17 (04) : 880 - 887
[2] Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
Mukai, Hirofumi
Takahashi, Shunji
Nozawa, Masahiro
Onozawa, Yusuke
Miyazaki, Jun
Ohno, Keiji
Suzuki, Kazuhiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 703 - 710
[3] Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
Hirofumi Mukai
Shunji Takahashi
Masahiro Nozawa
Yusuke Onozawa
Jun Miyazaki
Keiji Ohno
Kazuhiro Suzuki
Cancer Chemotherapy and Pharmacology, 2014, 73 : 703 - 710
[4] A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)
Ye, D.
Liu, R.
Luo, H.
Han, W.
Lu, X.
Cao, L.
Guo, P.
Liu, J.
Yue, Y.
Lu, C.
ANNALS OF ONCOLOGY, 2021, 32 : S643 - S643
[5] A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC)
Pinski, Jacek K.
Schally, Andrew V.
Tsao-Wei, Denice D.
Dorff, Tanya B.
Groshen, Susan G.
Xiong, Shigang
Quinn, David I.
Tai, Yu-Chong
Engel, Juergen
Liu, Stephen V.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] Phase I dose-escalation study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer
Carducci, Michael A.
Morris, Michael J.
Eisenberger, Mario A.
Pili, Roberto
Denmeade, Samuel R.
Slovin, Susan F.
Kelsen, Moshe
Jacobovits, Aya
Vincent, Martha
Scher, Howard I.
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3355S - 3355S
[7] Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer
Miura, Rieko
Hirabatake, Masaki
Irie, Kei
Ikesue, Hiroaki
Muroi, Nobuyuki
Kawakita, Mutsushi
Hashida, Tohru
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (04) : 233.e15 - 233.e20
[8] Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
Hummel, Horst-Dieter
Kufer, Peter
Grullich, Carsten
Deschler-Baier, Barbara
Chatterjee, Manik
Goebeler, Maria-Elisabeth
Miller, Kurt
De Santis, Maria
Loidl, Wolfgang C.
Buck, Andreas
Wittemer-Rump, Sabine
Koca, Goekben
Boix, Oliver
Doecke, Wolf-Dietrich
Stienen, Sabine
Sayehli, Cyrus
Bargou, Ralf C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[9] A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
Kolinsky, M. P.
Rescigno, P.
Bianchini, D.
Zafeirio, Z.
Mehra, N.
Mateo, J.
Michalarea, V.
Riisnaes, R.
Crespo, M.
Figueiredo, I.
Miranda, S.
Rodrigues, D. Nava
Flohr, P.
Tunariu, N.
Banerji, U.
Ruddle, R.
Sharp, A.
Welti, J.
Lambros, M.
Carreira, S.
Raynaud, F. I.
Swales, K. E.
Plymate, S.
Luo, J.
Tovey, H.
Porta, N.
Slade, R.
Leonard, L.
Hall, E.
de Bono, J. S.
ANNALS OF ONCOLOGY, 2020, 31 (05) : 619 - 625
[10] A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC).
Kyriakopoulos, Christos
Paller, Channing Judith
Verma, Ajit
Kader, Karim
Kittrelle, Jeff
Borgstrom, Per G.
Vaishampayan, Ulka N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →